Novel drug delivery system using thermo-reversible polymer for brain tumor
| Project/Area Number |
18591611
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
JOKI Tatsuhiro Jikei University School of Medicine, 医学部, 講師 (30226378)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJIGASAKI Junko 東京慈恵会医科大学, 医学部, 講師 (60312021)
|
|---|
| Project Period (FY) |
2006 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,210,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥810,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2007: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2006: ¥700,000 (Direct Cost: ¥700,000)
|
|---|
| Keywords | 脳腫瘍 / プロテオソーム阻害剤 / ポリマー / ドラッグデリバリー / プロテナソームインヒビター / ドラッグデリバリーシステム / プロテオソームインヒビター |
|---|
| Research Abstract |
MG132, a proteasome-inhibitor, has been shown to induce apoptosis of experimental malignant cells in vitro. However, its systemic toxicity prevents further use in clinical settings. To circumvent this toxicity, MG132 can be delivered directly to the tumor. We tested the efficacy of MG132 incorporated into thermoreversible gelation polymer (TGP) for treating experimental glioma cell lines were measured with MTT-assays. As a caspase activity assay, the activities for caspases 3, 8 and 9 were measured in a CytoFluor Multiwell Plate Reader. A significant increase in cleavage activities of caspases 3, 9, and 8 detected in caspase cleavage assay results was observed in both cell lines. MG132 exhibits potent cytotoxic-activity against U87MG and T98G in vitro, it can be efficiently incorporated and delivered using TGP.
|
Report
(6 results)
Research Products
(14 results)
